Scialpi Michele, Martorana Eugenio, Scialpi Pietro, D'Andrea Alfredo, Mancioli Francesco Maria, Mignogna Marcello, Blasi Aldo Di, Trippa Fabio
Division of Diagnostic Imaging, Department of Medicine and Surgery, University of Perugia, Santa Maria della Misericordia Hospital, Perugia, Italy.
Division of Urology, Nuovo Ospedale Civile Sassuolo, Modena, Italy.
Turk J Urol. 2021 Nov;47(6):448-451. doi: 10.5152/tud.2021.21274.
Prostate specific antigen (PSA) remains the most used test to assess the response after therapies including the radiation therapy (RT). Apparent diffusion coefficient (ADC) derived from the conventional diffusionweighted imaging (DWI), as a part of noncontrast or biparametric MRI (bpMRI) (T2-weighted and DWI), offers diagnostic accuracy and cancer detection rate equivalent to that of multiparametric MRI. Cellular changes induced by RT can be quali-qualitatively demonstrated as early as 3months after RT as an increase in the signal intensity of the tumor on the ADC map. ADC, in association with PSA, represents a potential biomarker imaging for evaluating treatment efficacy in PCa both during and shortly after RT.
前列腺特异性抗原（PSA）仍然是评估包括放射治疗（RT）在内的治疗后反应最常用的检测方法。源自传统扩散加权成像（DWI）的表观扩散系数（ADC），作为非对比或双参数MRI（bpMRI）（T2加权和DWI）的一部分，其诊断准确性和癌症检测率与多参数MRI相当。RT诱导的细胞变化最早可在RT后3个月定性地表现为ADC图上肿瘤信号强度增加。ADC与PSA相结合，代表了一种潜在的生物标志物成像，用于评估RT期间及RT后不久PCa的治疗效果。
